. N. Effect of SGLT2 inhibitor (Empagliflozin) on HbA1c in most Prevalent Age Group of Type 2 Diabetic Patients. Int J Pathol [Internet]. 2023 Mar. 10 [cited 2024 Nov. 24];20(4):178-81. Available from: https://jpathology.com/index.php/OJS/article/view/802